New Delhi: Drugs Controller General of India (DCGI) on Monday approved Biological E’s Covid-19 vaccine Corbevax for emergency use among children aged 12-18 years.
The Hyderabad-based pharmaceutical company’s vaccine had earlier received emergency use authorization from DCGI’s Subject Expert Committee for the 12-18 age group, subject to conditions.
Corbevax, to be administered in two doses, is the third vaccine to be approved for 12-18-year olds in India, the others being Bharat Biotech’s Covaxin and Zydus Cadila’s DNA shot ZyCoV-D.
However, Covaxin is mainly being used currently to inoculate children aged 15-18 years.
Corbevax is expected to cost Rs 145 per dose, excluding taxes, ANI reported quoting sources.
National Technical Advisory Group on Immunisation (NTAGI) chief Dr NK Arora said earlier that Corbevax shots were safe, and offered good immunogenicity and higher antibody levels compared to other vector vaccines.
Bhubaneswar: The Odisha Human Rights Commission (OHRC) has sent notices to Secretaries of Food &…
New Delhi: Even as his recently-released horror comedy ‘Bhool Bhulaiyaa 3’ continues to mint money…
New Delhi/Bhubaneswar: After over 20 days of investigation and analysing more than 700 CCTV cameras,…
New Delhi: The Delhi High Court has closed proceedings on a petition challenging the Rajiv…
Mumbai: ‘12th Fail’ actor Vikrant Massey recently got trolled after pictures of him touching his…
Mumbai: Mumbai Police swung into action immediately after Bollywood superstar Shah Rukh Khan received a…
Dubai: The effects of global climate change are being seen in various manifestations across the globe.…
Mumbai: When criminals are idolised and used for commercial purposes, police are bound to take action.…